Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 2,731 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 16, 2005, and the Company was advised of it on September 19, 2005.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Key Facts for Investor Verification
- Transaction Date: September 16, 2005.
- Shares Transferred: 2,731 Ordinary Shares.
- Source: GlaxoSmithKline Employee Trust (GSK Trust).
- Recipient: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Directors with Interest: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.
- Regulatory Basis: Disclosure Rule 3.1.4R(1)(b).